| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
As a chemical linker, N-Boc-N-bis(PEG1-OH) does not bind to biological targets. Its functional "targets" are the chemical groups on molecules to which it conjugates. The Boc-protected amine provides a protected nucleophile that can be deprotected under acidic conditions (e.g., TFA) to yield a free amine for conjugation to carboxylic acids (via amide bond formation using EDC/HATU activation) or other electrophiles. The two hydroxyl groups provide handles for further derivatization or for conjugation to carboxylic acids (via esterification). The PEG spacer improves aqueous solubility and biocompatibility of the final conjugates.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
As a synthetic linker molecule, this compound does not exhibit pharmacological activity in cell-based assays. Its in vitro utility is demonstrated through the successful synthesis and characterization of bioconjugates incorporating this linker. Researchers evaluate the linker's performance by assessing conjugation efficiency (via HPLC, LC-MS, or NMR), the stability of resulting conjugates in biological media, and the functional activity of final bioconjugates in target assays. The compound is soluble in DMSO and other organic solvents, facilitating its use in bioconjugation workflows. |
| ln Vivo |
No direct in vivo pharmacological activity is attributed to this compound. Its in vivo relevance is demonstrated through the performance of bioconjugates synthesized using this linker in animal models. The linker's stability in biological matrices and its contribution to the conjugate's pharmacokinetic profile are key parameters evaluated in preclinical studies. The Boc group is stable at physiological pH and is only deprotected under acidic conditions, ensuring that the construct remains intact during circulation. The compound is a research tool for bioconjugation and is not intended for therapeutic use.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to this compound as it is a chemical linker with no intrinsic affinity for biological macromolecules. Quality control and characterization are performed using standard analytical methods. Purity is assessed by HPLC (≥95%) and structural integrity is confirmed by ¹H NMR, ¹³C NMR, and mass spectrometry. The Boc-protected amine and hydroxyl groups are verified through spectroscopic analysis. For researchers using this linker, conjugation reactions are monitored by TLC, HPLC, or LC-MS. Deprotection of the Boc group is confirmed by NMR or LC-MS following acid treatment.
|
| Cell Assay |
Cell-based assays are not performed directly on this compound because it is a synthetic linker lacking biological activity. However, the biological activity of bioconjugates containing this linker is evaluated in relevant cell lines. Typical protocols involve treating cells with the bioconjugate and assessing the desired biological effect. The linker's contribution to the conjugate's cellular uptake, stability, and efficacy is inferred from comparative studies. DMSO stock solutions are prepared and diluted in cell culture media.
|
| Animal Protocol |
In vivo animal studies are conducted with bioconjugates incorporating this linker, not with the linker alone. Typical protocols utilize rodent models. The conjugate is administered via intravenous, intraperitoneal, or other routes at doses determined by preliminary pharmacokinetic and tolerability studies. Efficacy is assessed by measuring disease progression endpoints. The linker's stability in circulation is evaluated through plasma sampling and LC-MS/MS analysis.
|
| ADME/Pharmacokinetics |
As a chemical linker, this compound does not have a conventional pharmacokinetic profile. However, the pharmacokinetic properties of bioconjugates incorporating this linker are evaluated in preclinical studies. Following administration in rodents, key parameters such as half-life, clearance, volume of distribution, and bioavailability are determined from plasma concentration-time data. The PEG spacer contributes to enhanced aqueous solubility and reduced protein binding. Linker stability in plasma is assessed by measuring intact conjugate concentrations over time using LC-MS/MS.
|
| Toxicity/Toxicokinetics |
Standard laboratory safety precautions should be followed when handling this compound: use of personal protective equipment (gloves, safety goggles, lab coat) and handling in a well-ventilated fume hood. The compound should be stored at 0-4°C. No genotoxicity, carcinogenicity, or reproductive toxicity data are available. The compound is not classified as a hazardous drug but should be treated with care. Researchers should consult the safety data sheet (SDS) before handling and follow institutional chemical safety guidelines.
|
| References | |
| Additional Infomation |
Additional information: The compound has a CAS number of 275385-03-0. Its molecular formula is C₁₃H₂₇NO₆ and molecular weight is 293.36 g/mol. It is a PEG derivative with a Boc-protected amine and two hydroxyl groups. It is a branched PEG derivative. Purity is typically ≥95%. It appears as a pale yellow or colorless oily liquid. It is for research use only and is not approved for clinical applications. No FDA approvals exist.
|
| Molecular Formula |
C13H27NO6
|
|---|---|
| Molecular Weight |
293.356584787369
|
| Exact Mass |
293.183
|
| CAS # |
275385-03-0
|
| PubChem CID |
85773346
|
| Appearance |
Colorless to light yellow liquid（Density：1.121±0.06 g/cm3 No data available）
|
| LogP |
-0.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
20
|
| Complexity |
242
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)OC(=O)N(CCOCCO)CCOCCO
|
| InChi Key |
QKKAOQUTADWQAZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H27NO6/c1-13(2,3)20-12(17)14(4-8-18-10-6-15)5-9-19-11-7-16/h15-16H,4-11H2,1-3H3
|
| Chemical Name |
tert-butyl N,N-bis[2-(2-hydroxyethoxy)ethyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4088 mL | 17.0439 mL | 34.0878 mL | |
| 5 mM | 0.6818 mL | 3.4088 mL | 6.8176 mL | |
| 10 mM | 0.3409 mL | 1.7044 mL | 3.4088 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
